A Small-Molecule Screen for Enhanced Homing of Systemically Infused Cells

Cell Reports

Volumn 10, Issue 8, 2015, Pages 1261-1268

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROTEIN KINASE INHIBITOR; RO 31 8425; UNCLASSIFIED DRUG; ICAM1 PROTEIN, HUMAN; INDOLE DERIVATIVE; LIPOPOLYSACCHARIDE; MALEIMIDE DERIVATIVE; MOLECULAR LIBRARY; RO 31-8425;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL ENGINEERING; CELL HOMING; CELL SCREENING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; CELL MOTION; CHEMICALLY INDUCED; CHEMISTRY; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY;

ANIMALS; ANTIGENS, CD11A; CELL ADHESION; CELL LINE; CELL MOVEMENT; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLES; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LIPOPOLYSACCHARIDES; MALEIMIDES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES; UP-REGULATION;

EID: 84924542696     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.01.057     Document Type: Article

References (30)

1. Ankrum J., Karp J.M. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol. Med. 2010, 16:203-209.
2. Ankrum J.A., Ong J.F., Karp J.M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 2014, 32:252-260.
3. Bhatia S.K., King M.R., Hammer D.A. The state diagram for cell adhesion mediated by two receptors. Biophys. J. 2003, 84:2671-2690.
4. Brehmer D., Godl K., Zech B., Wissing J., Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell. Proteomics 2004, 3:490-500.
5. Cutler C., Multani P., Robbins D., Kim H.T., Le T., Hoggatt J., Pelus L.M., Desponts C., Chen Y.B., Rezner B., et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013, 122:3074-3081.
6. de Girolamo L., Lucarelli E., Alessandri G., Avanzini M.A., Bernardo M.E., Biagi E., Brini A.T., D'Amico G., Fagioli F., Ferrero I., et al. Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy. Curr. Pharm. Des. 2013, 19:2459-2473. Italian Mesenchymal Stem Cell Group.
7. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
8. Enoki C., Otani H., Sato D., Okada T., Hattori R., Imamura H. Enhanced mesenchymal cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction. Int. J. Cardiol. 2010, 138:9-18.
9. François M., Galipeau J. New insights on translational development of mesenchymal stromal cells for suppressor therapy. J.Cell. Physiol. 2012, 227:3535-3538.
10. Hoogduijn M.J., Popp F., Verbeek R., Masoodi M., Nicolaou A., Baan C., Dahlke M.H. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int. Immunopharmacol. 2010, 10:1496-1500.
11. Joy S.V., Scates A.C., Bearelly S., Dar M., Taulien C.A., Goebel J.A., Cooney M.J. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann. Pharmacother. 2005, 39:1693-1699.
12. Karp J.M., Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4:206-216.
13. Kim I., Moon S.O., Kim S.H., Kim H.J., Koh Y.S., Koh G.Y. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J.Biol. Chem. 2001, 276:7614-7620.
14. Ko I.K., Kim B.G., Awadallah A., Mikulan J., Lin P., Letterio J.J., Dennis J.E. Targeting improves MSC treatment of inflammatory bowel disease. Mol. Ther. 2010, 18:1365-1372.
15. Kumar S., Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. FASEB J. 2007, 21:3917-3927.
16. Levy O., Anandakumaran P., Ngai J., Karnik R., Karp J.M. Systematic analysis of invitro cell rolling using a multi-well plate microfluidic system. J.Vis. Exp. 2013, 80:e50866.
17. Levy O., Zhao W., Mortensen L.J., Leblanc S., Tsang K., Fu M., Phillips J.A., Sagar V., Anandakumaran P., Ngai J., et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 2013, 122:e23-e32.
18. Luster A.D., Alon R., von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005, 6:1182-1190.
19. Mortensen L.J., Levy O., Phillips J.P., Stratton T., Triana B., Ruiz J.P., Gu F., Karp J.M., Lin C.P. Quantification of Mesenchymal Stem Cell (MSC) delivery to a target site using invivo confocal microscopy. PLoS ONE 2013, 8:e78145.
20. Muid R.E., Dale M.M., Davis P.D., Elliott L.H., Hill C.H., Kumar H., Lawton G., Twomey B.M., Wadsworth J., Wilkinson S.E., et al. A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli. FEBS Lett. 1991, 293:169-172.
21. Newell E.W., Sigal N., Nair N., Kidd B.A., Greenberg H.B., Davis M.M. Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat. Biotechnol. 2013, 31:623-629.
22. Prockop D.J., Oh J.Y. Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results invivo to the cellular and molecular explanations. J.Cell. Biochem. 2012, 113:1460-1469.
23. Rombouts W.J., Ploemacher R.E. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003, 17:160-170.
24. Sackstein R., Merzaban J.S., Cain D.W., Dagia N.M., Spencer J.A., Lin C.P., Wohlgemuth R. Exvivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 2008, 14:181-187.
25. Sarkar D., Spencer J.A., Phillips J.A., Zhao W., Schafer S., Spelke D.P., Mortensen L.J., Ruiz J.P., Vemula P.K., Sridharan R., et al. Engineered cell homing. Blood 2011, 118:e184-e191.
26. Song B.W., Chang W., Hong B.K., Kim I.K., Cha M.J., Lim S., Choi E.J., Ham O., Lee S.Y., Lee C.Y., et al. Protein kinase C activation stimulates mesenchymal stem cell adhesion through activation of focal adhesion kinase. Cell Transplant. 2013, 22:797-809.
27. Tang S., Xiao V., Wei L., Whiteside C.I., Kotra L.P. Protein kinase C isozymes and their selectivity towards ruboxistaurin. Proteins 2008, 72:447-460.
28. Teo G.S., Ankrum J.A., Martinelli R., Boetto S.E., Simms K., Sciuto T.E., Dvorak A.M., Karp J.M., Carman C.V. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 2012, 30:2472-2486.
29. Tong Z., Duncan R.L., Jia X. Modulating the behaviors of mesenchymal stem cells via the combination of high-frequency vibratory stimulations and fibrous scaffolds. Tissue Eng. Part A 2013, 19:1862-1878.
30. Wong D., Dorovini-Zis K. Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide. J.Neuroimmunol. 1992, 39:11-21.